American Journal of Obstetrics & Gynecology
Volume 197, Issue 3 , Pages 262.e1-262.e4 , September 2007

Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting

This study was presented at the 27th Annual Clinical Meeting of the Society for Maternal–Fetal Medicine, San Francisco, CA, Feb. 5-10, 2007.

  • Charles Rittenberg, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC
    • Corresponding Author InformationReprints: Charles Rittenberg, MD, Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas St, Suite 634, P.O. Box 250619, Charleston, SC 29425
    • ,
  • Scott Sullivan, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC
    • ,
  • Niki Istwan, RN

      Affiliations

    • Clinical Research, Matria Healthcare, Marietta, GA.
    • ,
  • Debbie Rhea, MPH

      Affiliations

    • Clinical Research, Matria Healthcare, Marietta, GA.
    • ,
  • Gary Stanziano, MD

      Affiliations

    • Clinical Research, Matria Healthcare, Marietta, GA.
    • ,
  • Roger Newman, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC

Received 12 March 2007 ,Revised 4 May 2007 ,Accepted 15 June 2007.

References 

  1. Meis PJ, Klevanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–2385
  2. American College of Obstetricians and Gynecologists. ACOG committee opinion, number 291 (Use of progesterone to reduce preterm birth). Obstet Gynecol. 2003;102:1115–1116
  3. Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol. 2006;195:1174–1179
  4. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357:454–461
  5. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ. Gestational age at initiation of 17 alpha-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med. 2007;20:249–252
  6. Rebarber A, Ferrara LA, Hanley ML, et al. Increased recurrence of preterm delivery with early cessation of 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;224:e1–e4

 Cite this article as: Rittenberg C, Sullivan S, Istwan N, et al. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol 2007;197:262.e1-262.e4.

PII: S0002-9378(07)00761-2

doi: 10.1016/j.ajog.2007.06.032

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3 , Pages 262.e1-262.e4 , September 2007

Article Tools